BioValence Sdn. Bhd. began in 2011 with only 3 staff. Today, we have 4 laboratories and employ about 20 scientific staff at any one time. BioValence has a paid up capital of RM6 million and has been awarded several competitive grants for the commercialization of our technology platforms.
We are a leading Malaysian drug discovery company that works on human viruses such as Dengue and Zika, companion animal viruses such as Canine Parvovirus 2 and Feline Leukemia, as well as shrimp diseases such as WSSV and Early Mortality Syndrome. Our leading drug candidate RetroMAD1 is a recombinant protein that possesses broad spectrum antiviral properties. It survives digestive enzymes for 2 hours and will appear in the serum within 30 minutes of feeding in rats, mice and monkeys (with 39% bioavailability). In mice, even a 250x therapeutic dose (used for Feline Leukemia) does not result in any adverse reaction in CBC, biochemistry and histopathology. The protein does not require cold chain transport and is easily upscalable in bioreactors followed by lysis and protein refolding.
Our corporate strategy is to find investors and/or corporate partners to take RetroMAD1 to the USA, EU and China for their lucrative companion animal markets passing through their respective regulatory processes. Pilot studies involving around 500 client pets in 4 countries have already given promising results. We also need developmental partners for Dengue and possibly Zika. Currently, we have collaborations with Cambridge University and the National University of Singapore for the use of RetroMAD1 for Dengue as an antiviral therapeutic. RetroMAD1 also has in vitro activity against Ebola and we also seek partnerships in biological defence initiatives. Patents have been granted in USA, Australia and Singapore.
We have accumulated sufficient expertise to develop more oral delivery broad spectrum antiviral proteins for a future pipeline.
Fundamental Research Laboratory
Located in 3 Two Square, Petaling Jaya, the fundamental research laboratory is a biosafety-compliant facility which houses two different research areas: mammalian cell culture (virology), and protein-related research. This laboratory is certified for the handling of BSL-2 organisms.
Upscale Optimization Laboratory
Located in Taman Mayang, Kelana Jaya, the upscale optimization lab is a biosafety-compliant facility which houses upscale production from 10 L to 75 L.
Clinical Batch Production Laboratory
Located in Petaling Utama Avenue, Petaling Jaya, the clinical batch production facility houses an ISO Class 8 Cleanroom which is yet to be audited and certified. The intended use of this facility is for manufacturing the active pharmaceutical ingredient (API) for pre-clinical testing and clinical phase I.
Shrimp Disease Centre (SDC)
Located in 3 Two Square, Petaling Jaya, the Shrimp Disease Centre (SDC) was set up to conduct research into two areas: the mitigation of shrimp diseases, and water quality management. This facility focuses on using microbiology approaches to achieve these two objectives.
- University of Stirling, United Kingdom: In vitro testing on Infectious Pancreatic Necrosis Virus (IPNV)
- University of Malaya (UM), Malaysia: Next Gen Sequencing on Early Mortality Syndrome (EMS)-causing Vibrio parahaemolyticus; acute and sub-chronic toxicology rat studies for RetroMAD1
- National University of Singapore (NUS), Singapore: Dengue mouse model for testing of RetroMAD1
- National Institutes of Health (NIH), USA: Testing of RetroMAD1 on HIV-1 humanized mouse model
- United States Army Medical Research Institute of infectious diseases (USAMRIID), USA: In vitro testing of RetroMAD1 for Ebola Virus (EBOV) and Zika Virus (ZIKV).
- Commonwealth Scientific and Industrial Research Organization (CSIRO), Australia: In vivo testing of RetroMAD1 Ebola Virus (EBOV)-infected mice